Mangoceuticals’ oral Semaglutide weight loss treatment marketed and branded under the name ‘Slim,’ is now available for purchase on the company’s website. According to the New England Journal of Medicine, Semaglutide has become widely recognized for its effectiveness in aiding weight loss by regulating appetite and promoting a feeling of fullness. MangoRx’s formulation is available as an oral dissolvable tablet and compounded with Vitamin B6. The company anticipates leveraging the increasing demand for GLP-1 peptides, including Semaglutide, to increase revenues in the coming quarters.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- Mangoceuticals Raises Capital and Boosts CEO Perks
- Mangoceuticals files 16.17M shares of common stock for holders
- Mangoceuticals reports 1H revenue $377,258 vs. $241,959 last year
- Mangoceuticals receives patent in India, initiates clinical trials
- Mangoceuticals completes migration to DEA-approved telemedicine platform